^
Association details:
| Biomarker: | IDH2 R140 |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Idhifa (enasidenib) (IDH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
636 Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial
Published date:
11/04/2020
Excerpt:
Responses were higher (p=0.04) among the 44 pts with IDH2 R140 (55%) as compared to the 16 with IDH2 R172 mutation (25%) further supporting distinct biology between these subsets....ENA had a low early death rate, high CR/CRi rate (47%, adjusted 95% CI 28-59), and yielded durable remissions.
Trial ID:
Source:
Title:
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Excerpt:
The ORR for patients with IDH2-R172 mutationss was 35.4% (95% CI, 27.2%-44.2%) and for those with IDH2-R172 mutations, ORR was 53.3% (95% CI, 37.9%-68.3%). Rates of complete remission were 17.7% (95% CI, 11.6%-25.4%) in patients with IDH2-R140 mutations and 24.4% (95% CI, 12.9%-39.5%) for patients with IDH2-R172 mutations....In conclusion, data from this study showed that single-agent enasidenib was well tolerated, induced hematologic responses, and was associated with a median survival of more than 9 months in patients with relapsed or refractory mutant-IDH2 AML.
DOI:
10.1182/blood-2017-04-779405
Trial ID: